ArticleNature2012
Genomics: the breast cancer landscape.
Article in Nature, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Biological effect of ribosomal protein L32 on human breast cancer cell behavior.Molecular medicine reports · 2020Article
- The effect of interleukin 10 polymorphisms on breast cancer susceptibility in Han women in Shaanxi Province.PloS one · 2020Article
- Clinical analysis of 21-gene recurrence score test in hormone receptor-positive early-stage breast cancer.Oncology letters · 2019Article
- Expression, Clinical Significance, and Functional Prediction of MNX1 in Breast Cancer.Molecular therapy. Nucleic acids · 2018Article
- Autophagy, Cell Viability, and Chemoresistance Are Regulated By miR-489 in Breast Cancer.Molecular cancer research : MCR · 2018Article
- Deciphering the roles of lncRNAs in breast development and disease.Oncotarget · 2018Review
- Article
- Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients.PloS one · 2017Article
- Article
- Predicting chemoinsensitivity in breast cancer with 'omics/digital pathology data fusion.Royal Society open science · 2016Article
- Eavesdropping on altered cell-to-cell signaling in cancer by secretome profiling.Molecular & cellular oncology · 2016Article
- Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Oncotarget · 2015Article
- Article
- High-throughput gene expression and mutation profiling: current methods and future perspectives.Breast care (Basel, Switzerland) · 2013Review
- Metasignatures identify two major subtypes of breast cancer.CPT: pharmacometrics & systems pharmacology · 2013Article
- Review
- Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.Expert review of molecular diagnostics · 2013Review
- Translating metastasis-related biomarkers to the clinic--progress and pitfalls.Nature reviews. Clinical oncology · 2013Review
- What are we learning from the cancer genome?Nature reviews. Clinical oncology · 2012Review
Corrections and comments
- Comment on
- Comment on
- Comment on
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
22722187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.